The Aromatase Inhibitors as Adjuvant Therapy for Hormone Receptor-Positive Breast Cancer

Journal of the National Comprehensive Cancer Network : JNCCN - United States
doi 10.6004/jnccn.2003.0020
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Harborside Press, LLC

Related search

Efficacy of Adjuvant Aromatase Inhibitor in Hormone Receptor-Positive Postmenopausal Breast Cancer Patients According to the Body Mass Index

British Journal of Cancer
Cancer ResearchOncology
2012English

Bisphosphonates as Adjuvant Therapy for Breast Cancer

Women's Health
Medicine
2006English

MiR-4653-3p and Its Target Gene FRS2 Are Prognostic Biomarkers for Hormone Receptor Positive Breast Cancer Patients Receiving Tamoxifen as Adjuvant Endocrine Therapy

Oncotarget
Oncology
2016English

Treatment of Hormone Positive Uterine Leiomyosarcoma With Aromatase Inhibitors

Clinical Sarcoma Research
Oncology
2014English

Low P27 Expression Predicts Early Relapse and Death in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients Receiving Adjuvant Tamoxifen Therapy

Clinical Cancer Research
Cancer ResearchOncology
2009English

Oral Bisphosphonates as Adjuvant Therapy for Operable Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2006English

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2016English

CDK4/6 Inhibitors for Hormone Receptor-Positive HER2-negative Metastatic Breast Cancer: Does One Size Fit All?

Future Medicinal Chemistry
Drug DiscoveryMolecular MedicinePharmacology
2019English

Progesterone Receptor Expression in Proliferating Cancer Cells of Hormone-Receptor-Positive Breast Cancer

Tumor Biology
MedicineCancer Research
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy